UNSPSC 51241103: Bimatoprost

This classification denotes a prostaglandin analogue and anti-glaucoma agent with the molecular formula C25H37NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QXS94885MZ, chemically known as 5-heptenamide, 7-(3,5-dihydroxy-2-(3-hydrdoxy-5-phenyl-1-pentenyl)cyclopentyl)-n-ethyl-, (1r-(1alpha(z),2beta(1e,3s*),3alpha,5alpha))- but generally known as bimatoprost, which bears US NIH Compound Identifier 5311027.

UNSPSC 51241103 Bimatoprost is a Commodity code covering a specific ophthalmic pharmaceutical product. Recent state and local activity under this code shows minimal independent solicitation; instead, bimatoprost appears as one item within broader multi-source generic pharmaceutical RFPs issued by cooperative purchasing alliances. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, uses this and related pharmaceutical codes to classify products within master agreements serving state agencies, local government facilities, and participating jurisdictions across multiple states including Oregon. Issuing bodies under pharmaceutical commodity codes are predominantly state purchasing offices and cooperative purchasing vehicles that aggregate demand across state and local entities; individual municipalities and school districts typically purchase through these cooperative contracts rather than issuing independent solicitations for specific drug products.

The most recent opportunity is MMCAP's January 2026 RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026. MMCAP requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and emphasizes cGMP certification, Drug Supply Chain Security Act compliance, and pricing flexibility across flat-price, net-price, or WAC-minus formats. The evaluation is price-heavy (75 percent weight) with administrative compliance and EDI capability scoring the remainder. Geographic activity concentrates in the upper Midwest and Pacific Northwest, driven by MMCAP's multi-state footprint. Vendors pursuing pharmaceutical commodity codes should expect to participate in cooperative purchasing master agreements rather than jurisdiction-specific spot buys, and should be prepared to maintain relationships with major pharmaceutical wholesalers and meet strict regulatory and insurance requirements.